
SARS-COV-2 NSP7&NSP8 Protein

Cat. No. NSP-VE178

Description SARS-COV-2 NSP7&NSP8 Protein is expressed from E.coil with His tag at the C-Terminus. Source It contains Ser1-Gln83(NSP7)&Ala1-Gln198(NSP8). Accession YP 009725303.1(NSP7)&YP 009725304.1(NSP8) Molecular The protein has a predicted MW of 32.8 kDa same as Bis-Tris PAGE result. Weight Endotoxin Less than 1EU per µg by the LAL method. Purity > 95% as determined by Bis-Tris PAGE Formulation and Storage Lyophilized from 0.22µm filtered solution in 20mM Tris, 150mM Nacl, 200mM Arginine (pH 8.2). Normally 8% Formulation trehalose is added as protectant before lyophilization. Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Reconstitution Dissolve the lyophilized protein in distilled water. -20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3 months after reconstitution. Recommend Storage to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. Background The crystal structure of the metabolite of remdesivir (Monophosphate of GS-441524) and NSP12-NSP8-NSP7 of SARS CoV-2 virus was recently reported. The crystal structures of ADP-Ribose or AMP and NSP3 of SARS CoV-2 virus were also released, recently. The crystal structure of NSP3 of SARS CoV-2 virus as an alternative binding site of AMP or ADP-ribose to treat COVID-19.

Assay Data

Bis-Tris PAGE



SARS-COV-2 NSP7&NSP8 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

 $K\Lambda$